The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: ACTOS

Takeda Canada’s Opening Move: Reacquire Rights to Diabetes Drug ACTOS from Eli Lilly Canada

Takeda Canada, which opened in Mississauga in March, bought back the commercial rights to pioglitazone HCl, a type 2 diabetes drug marketed as ACTOS, from Eli Lilly Canada. Financial terms were not disclosed. Lilly had been marketing the drug in Canada under a 1999 worldwide agreement with Takeda.

Takeda Canada general manager Daaron Dohler characterized the move as “Takeda’s first opportunity to establish a commercial presence in Canada.” The company has job postings up for a manager of sales and marketing operations and two marketing directors.

Having said in March that they were targeting an NDS submission for the end of 2009, I wonder if this move points toward another diabetes product… Stay tuned.

Update: FierceBiotech’s post on the transaction this morning also notes the “boost” ACTOS got last week from the results of a comparative study against GSK’s Avandia.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 129 other followers